Get started
Work

A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence

Year: 2015
Type: article
Abstract: Meeting abstracts There is currently no consensus on the standard of care for pts with completely resected stage IIIB/C or stage IV MEL with no evidence of disease (NED) who are at high risk for recurrence. NIVO, a PD-1 immune checkpoint inhibitor, is approved in the United States, Europe, and
DOI: 10.1186/2051-1426-3-s2-p166
Authors: Jeffrey Weber, Jean-Jaques Grob, Kim A Margolin, Paolo A Ascierto, Mario Sznol, Patrick A Ott, Chantal Lejeune, Veerle de Pril, Mary M Ruisi, F Stephen Hodi
Institutions: Moffitt Cancer Center, Aix-Marseille Université, Hôpital de la Timone, Stanford Medicine, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Yale Cancer Center, Dana-Farber Cancer Institute, Bristol-Myers Squibb (United States)
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $2,490
OpenAlex ID: W2187248191
FWCI: 1.04
Cites:
Cited by: 11
Related to: 10